%20%E2%80%93%20Book%20Review%20&%20Clinical%20Reference.webp "Physicians' Cancer Chemotherapy Drug Manual 2024 (Twenty-Fourth Edition) – Book Review & Clinical Reference")
What is the Physicians' Cancer Chemotherapy Drug Manual, 2024?
Physicians' Cancer Chemotherapy Drug Manual 2024 (Twenty-Fourth Edition) is a practical oncology reference edited by Edward Chu and Vincent T. DeVita Jr. It provides concise, up-to-date information on anticancer drugs, chemotherapy dosing, treatment regimens, dose modifications, and supportive care, making it a valuable resource for oncologists, oncology trainees, pharmacists, and other healthcare professionals involved in cancer care.
Introduction
Cancer treatment continues to evolve rapidly as new targeted therapies, biologic agents, immunotherapies, and precision medicine approaches become integrated into everyday oncology practice. Healthcare professionals caring for patients with cancer require access to current, reliable, and clinically focused drug information that can be consulted efficiently during patient care.
Physicians' Cancer Chemotherapy Drug Manual 2024 (Twenty-Fourth Edition) is designed to serve this need by providing a practical reference on contemporary anticancer medications and commonly used chemotherapy regimens.
Rather than functioning as a traditional oncology textbook that emphasizes disease biology or comprehensive cancer management, this manual focuses on the practical aspects of systemic anticancer therapy, including drug mechanisms, approved indications, dosage recommendations, pharmacology, toxicity profiles, drug interactions, and important clinical precautions.
The editors explain that the manual has been updated to incorporate newly approved agents and expanded indications, while maintaining a concise and clinically accessible format.
The preface highlights the continuing advances in cancer pharmacology driven by developments in molecular biology, pharmacogenomics, genomics, proteomics, and the identification of novel therapeutic targets. These advances have expanded the therapeutic options available for patients and increased the complexity of oncology practice, making regularly updated clinical references increasingly valuable.
According to the editors, the Twenty-Fourth Edition includes updates reflecting information gathered during the previous year, introduces 12 newly approved anticancer agents, and incorporates several newly approved supplemental FDA indications for previously available drugs.
The book is intended to function both as an in-depth reference and as a practical point-of-care resource for physicians and other healthcare professionals involved in the daily management of patients with cancer.
Because of its emphasis on clinical applicability, the manual may be useful for:
- Medical oncologists
- Hematologists
- Oncology fellows
- Internal medicine residents
- Oncology pharmacists
- Advanced practice providers
- Oncology nurses
- Medical students undertaking oncology rotations
Its concise organization allows clinicians to rapidly locate essential prescribing information while also providing sufficient scientific background to understand drug mechanisms and therapeutic applications.
Book Overview
|
Item |
Details |
|
Full
Title |
Physicians' Cancer Chemotherapy Drug
Manual 2024 |
|
Edition |
Twenty-Fourth Edition (2024) |
|
Editors |
Edward Chu, MD, MMS, FACP; Vincent
T. DeVita, Jr., MD |
|
Publisher |
Jones & Bartlett Learning |
|
Publication
Year |
2024 |
|
ISBN |
978-1-284-00000-9 |
|
Medical
Specialty |
Medical Oncology / Cancer
Pharmacology / Chemotherapy |
|
Primary
Focus |
Anticancer drugs, biologic
therapies, chemotherapy dosing, treatment regimens, supportive oncology care |
|
Intended
Audience |
Physicians, oncology fellows,
residents, pharmacists, oncology nurses, medical students, and healthcare
professionals involved in cancer treatment |
The editorial leadership reflects extensive experience in academic oncology and cancer pharmacology. The editors are affiliated with the Montefiore Einstein Comprehensive Cancer Center and Yale Cancer Center, respectively, while contributing authors include practicing oncologists, academic faculty members, and oncology specialists.
WHAT THIS BOOK COVERS
Principles of Cancer Chemotherapy
The opening chapter introduces the scientific and clinical foundations of systemic cancer therapy. Topics include:
- Historical development of chemotherapy
- Modern molecular oncology
- Pharmacogenomics
- Genomics and proteomics
- Molecular targets for anticancer drug development
- Mechanisms underlying treatment response and drug resistance
- Clinical applications of chemotherapy
- Principles of combination chemotherapy
The chapter also discusses the major clinical settings in which chemotherapy is used, including primary induction therapy, neoadjuvant therapy, adjuvant therapy, and regional or site-directed chemotherapy. In addition, it reviews the rationale for combination chemotherapy and factors influencing treatment duration.
Comprehensive Review of Chemotherapeutic and Biologic Drugs
The largest section of the manual is devoted to individual anticancer agents arranged alphabetically by their generic names.
For each medication, the editors consistently provide information such as:
- Drug classification
- Therapeutic category
- Trade names
- Drug manufacturer
- Mechanism of action
- Mechanisms of resistance
- Pharmacokinetics
- Drug absorption
- Distribution
- Metabolism
- FDA-approved indications
- Recommended dosage ranges
- Drug interactions
- Clinical precautions
- Monitoring recommendations
- Toxicity profiles
Early examples in the text include targeted therapies, antibody-drug conjugates, immunotherapies, hormonal therapies, taxanes, cytokines, and numerous other modern oncology agents, illustrating the breadth of pharmacologic coverage provided throughout the manual.
Chemotherapy Dose Modifications
A dedicated chapter addresses practical issues encountered during treatment planning, including recommendations for chemotherapy dose adjustment.
According to the table of contents and preface, this section includes guidance regarding:
- Myelosuppression
- Hepatic dysfunction
- Renal dysfunction
- Dose modifications
- Teratogenic potential of anticancer drugs
Such information supports clinicians who must individualize therapy according to patient-specific clinical circumstances.
Common Chemotherapy Regimens
The manual also includes a chapter reviewing commonly used chemotherapy combinations and selected single-agent regimens.
The editors state that these regimens are organized alphabetically according to cancer type and include both solid tumors and hematologic malignancies commonly encountered in clinical practice.
Supportive Oncology Care
Recognizing that supportive care remains essential in oncology practice, the final chapter focuses on antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV).
This section reviews:
- Common antiemetic agents
- Antiemetic regimens
- Management of chemotherapy-induced nausea and vomiting
The editors identify CINV as one of the significant toxicities associated with many anticancer treatments currently used in clinical practice.
Key Features
- Comprehensive reference covering contemporary anticancer medications.
- Updated Twenty-Fourth Edition published in 2024.
- Includes 12 newly introduced anticancer agents and newly approved FDA supplemental indications reported by the editors.
- Organized alphabetically for rapid drug lookup.
- Consistent format for every drug monograph.
- Detailed descriptions of mechanisms of action and resistance.
- Practical dosing recommendations and dosage ranges.
- Drug interaction summaries.
- Guidance for hepatic and renal dose modification.
- Toxicity monitoring recommendations.
- Clinical precautions and special considerations.
- Chapter dedicated to commonly used chemotherapy regimens.
- Dedicated section covering antiemetic therapy for chemotherapy-induced nausea and vomiting.
- Designed as both a quick-reference guide and an educational oncology resource.
Who Should Read This Book
Medical Students
Students completing oncology, hematology, pharmacology, or internal medicine rotations can use this manual to become familiar with commonly prescribed anticancer drugs and the principles of systemic cancer treatment. The concise organization may complement larger oncology textbooks by providing practical drug-specific information.
Residents and Fellows
Residents in internal medicine, hematology, oncology, surgery, radiation oncology, and related specialties may benefit from the manual's emphasis on clinically relevant prescribing information, toxicity recognition, dosing considerations, and treatment regimens used in routine practice.
Medical Oncologists and Hematologists
Practicing specialists can use the manual as a point-of-care reference when reviewing drug indications, monitoring recommendations, toxicity profiles, and chemotherapy dosing principles. The editors describe the book as an immediate source of practical clinical information for professionals involved in daily cancer care.
Oncology Pharmacists
Pharmacists involved in oncology services may find value in the detailed discussions of pharmacology, drug interactions, pharmacokinetics, dosage recommendations, and monitoring considerations presented throughout the manual.
Oncology Nurses and Advanced Practice Providers
Healthcare professionals responsible for administering chemotherapy and monitoring treatment-related adverse effects may benefit from the practical summaries of toxicities, precautions, supportive care, and monitoring recommendations included for individual agents.
Why This Book Is Useful
A Practical Point-of-Care Oncology Reference
One of the primary strengths of Physicians' Cancer Chemotherapy Drug Manual 2024 (Twenty-Fourth Edition) is its focus on practical clinical decision-making. Instead of presenting lengthy discussions of cancer biology, the manual concentrates on information clinicians frequently need during routine patient care.
Each drug monograph follows a standardized structure, allowing readers to quickly locate essential prescribing information. Typical sections include:
- Mechanism of action
- Mechanism of resistance
- Pharmacokinetics
- FDA-approved indications
- Dosage recommendations
- Drug interactions
- Special clinical considerations
- Toxicity profile
This consistent organization makes the manual easy to navigate whether it is being used in outpatient oncology clinics, inpatient services, infusion centers, or educational settings.
Reflects Contemporary Oncology Practice
The editors state that the Twenty-Fourth Edition has been updated with information published during the preceding year and includes:
- Twelve newly approved anticancer agents
- Newly approved supplemental FDA indications for existing therapies
- Updated chemotherapy information reflecting ongoing advances in cancer pharmacology
The preface emphasizes that modern oncology continues to evolve rapidly through advances in molecular biology, pharmacogenomics, genomics, proteomics, and the identification of new therapeutic targets. These developments have substantially expanded available treatment options, making regularly updated references increasingly valuable for healthcare professionals.
Emphasis on Safe Medication Use
The manual extends beyond simple drug descriptions by including practical safety information that supports clinical prescribing.
For individual medications, readers will commonly find guidance regarding:
- Organ function considerations
- Monitoring recommendations
- Drug–drug interactions
- Dose modification
- Important precautions
- Common and serious toxicities
For example, drug monographs include recommendations for laboratory monitoring, hepatic and renal impairment considerations, bleeding risk, infection monitoring, and pregnancy-related precautions when applicable. These practical details are incorporated throughout the individual drug entries.
Useful for Learning New Targeted Therapies
Modern oncology increasingly relies on targeted therapies and biologic agents.
The uploaded source demonstrates this by including detailed monographs for newer agents such as:
- Acalabrutinib
- Adagrasib
- Ado-trastuzumab emtansine
- Afatinib
- Albumin-bound paclitaxel
- Aldesleukin
- Alectinib
Each monograph discusses the drug's mechanism of action, resistance mechanisms, pharmacokinetics, approved indications, dosage recommendations, drug interactions, special considerations, and toxicity profile using a standardized format.
Helpful for Evidence-Informed Clinical Practice
Although the manual is primarily designed as a practical drug reference rather than a comprehensive oncology textbook, it incorporates information on:
- FDA-approved indications
- Recommended dosing
- Clinical monitoring
- Toxicity recognition
- Pharmacologic characteristics
The editors also note that treatment recommendations continue to evolve rapidly and encourage readers to remain aware of newly emerging data and regulatory updates.
Supports Efficient Learning
Because every medication follows the same organizational pattern, readers can efficiently compare drugs within the same therapeutic class.
For trainees preparing for oncology rotations or reviewing anticancer pharmacology, this structured presentation may facilitate learning by allowing rapid identification of:
- Mechanism of action
- Clinical indications
- Pharmacokinetics
- Important adverse effects
- Monitoring recommendations
This standardized format also makes the manual convenient for quick review before patient encounters or multidisciplinary discussions.
Table of Contents Overview
Based on the uploaded source, the manual is organized into five major sections:
Chapter 1 – Principles of Cancer Chemotherapy
Introduces the foundations of systemic anticancer therapy, including:
- History of chemotherapy
- Molecular oncology
- Pharmacogenomics
- Drug development
- Chemotherapy mechanisms
- Clinical applications
- Combination chemotherapy
- Treatment duration
Chapter 2 – Chemotherapeutic and Biologic Drugs
The largest chapter in the book.
Contains alphabetically arranged monographs covering anticancer medications, including:
- Conventional chemotherapy
- Targeted therapy
- Immunotherapy
- Hormonal therapy
- Antibody-drug conjugates
- Biologic response modifiers
Each monograph follows a standardized structure covering pharmacology, indications, dosage, interactions, precautions, and toxicities.
Chapter 3 – Dose Modification Guidelines
Provides guidance on chemotherapy dose adjustment in situations such as:
- Myelosuppression
- Hepatic dysfunction
- Renal dysfunction
- Teratogenicity
Chapter 4 – Common Chemotherapy Regimens
Includes commonly used chemotherapy protocols and selected single-agent regimens organized by disease type.
Chapter 5 – Antiemetic Therapy
Reviews medications and treatment strategies for chemotherapy-induced nausea and vomiting (CINV), an important component of supportive oncology care.
Strengths of the Book
Comprehensive Drug Coverage
The manual covers a broad spectrum of anticancer therapies, ranging from traditional cytotoxic chemotherapy to modern targeted therapies, biologic agents, antibody-drug conjugates, and immunotherapies.
Standardized Drug Monographs
Every medication is presented using a consistent format, making information easy to locate during clinical practice.
Clinically Focused
The emphasis is on information directly relevant to patient management rather than extensive theoretical discussion.
Updated Edition
The editors specifically note inclusion of newly approved anticancer agents and updated FDA indications available at the time of publication.
Practical Monitoring Recommendations
Drug monographs include clinically useful recommendations regarding:
- Laboratory monitoring
- Drug interactions
- Organ dysfunction
- Toxicity surveillance
- Dose modification
These features enhance the manual's usefulness as a point-of-care reference.
Concise Yet Information-Dense
The manual balances brevity with substantial clinical detail, allowing rapid consultation without sacrificing important prescribing information.
Limitations
Designed as a Drug Manual
The manual primarily focuses on anticancer medications and treatment regimens rather than providing comprehensive discussions of cancer diagnosis, pathology, staging, imaging, or surgical management. Readers seeking extensive disease-specific reviews may require additional oncology textbooks.
Rapidly Evolving Field
The editors acknowledge that oncology drug development continues to advance rapidly. Consequently, newer drug approvals, expanded indications, or updated regulatory guidance released after publication will not be reflected in this edition.
Focus on Systemic Therapy
Supportive care topics are included, but the principal emphasis remains systemic anticancer pharmacotherapy rather than the broader multidisciplinary management of cancer.
Comparison With Similar Books
Within the field of oncology pharmacotherapy, Physicians' Cancer Chemotherapy Drug Manual 2024 occupies a distinct niche as a concise drug reference.
Compared with comprehensive oncology textbooks such as DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, this manual emphasizes practical prescribing information and rapid drug lookup rather than extensive discussions of disease biology, epidemiology, and multidisciplinary cancer management.
Compared with larger pharmacology references, its standardized monograph format facilitates quick access to information on drug mechanisms, indications, dosing, interactions, precautions, and toxicities. This comparison reflects the general scope and organization of these works rather than asserting superiority. The uploaded source does not contain direct comparative evaluations.
Physicians' Cancer Chemotherapy Drug Manual 2024
FAQs
It is a practical oncology drug reference edited by Edward Chu and Vincent T. DeVita Jr. that summarizes anticancer medications, chemotherapy regimens, dosing recommendations, drug interactions, toxicities, and supportive care information for healthcare professionals.
According to the uploaded source, the manual is intended for physicians and other healthcare professionals involved in cancer treatment. It is also likely to be useful for oncology trainees, pharmacists, nurses, and medical students seeking a concise clinical drug reference.
Yes. The uploaded source includes numerous targeted therapies and biologic agents presented in detailed drug monographs alongside conventional chemotherapy agents.
Yes. Individual drug monographs include recommended dosage ranges together with important prescribing considerations when available.
Yes. Drug monographs include toxicity profiles, monitoring recommendations, drug interactions, and special clinical considerations for individual anticancer medications.
Yes. The editors state in the preface that the Twenty-Fourth Edition incorporates 12 newly approved anticancer agents together with newly approved supplemental FDA indications available during the revision period.
Conclusion
Physicians' Cancer Chemotherapy Drug Manual 2024 (Twenty-Fourth Edition) is a concise, clinically oriented reference designed to support healthcare professionals involved in the delivery of systemic cancer therapy.
Edited by Edward Chu, MD, MMS, FACP, and Vincent T. DeVita, Jr., MD, the manual emphasizes practical prescribing information for anticancer drugs while incorporating updates that reflect advances in oncology pharmacology and FDA-approved therapies available at the time of publication.
Unlike comprehensive oncology textbooks that extensively discuss tumor biology, staging, pathology, and multidisciplinary management, this manual focuses on the pharmacologic aspects of cancer treatment.
Individual drug monographs provide standardized information on mechanisms of action, mechanisms of resistance, pharmacokinetics, approved indications, dosage recommendations, drug interactions, monitoring parameters, special clinical considerations, and toxicity profiles. This consistent structure enables readers to locate clinically relevant information efficiently during patient care.
The editors also describe updates included in this edition, including the addition of 12 newly approved anticancer agents and several newly approved supplemental FDA indications, reflecting the rapidly evolving landscape of modern oncology.
The manual further includes chapters covering the principles of cancer chemotherapy, chemotherapy dose modification, commonly used chemotherapy regimens, and antiemetic therapy for chemotherapy-induced nausea and vomiting, making it a practical companion for clinicians managing patients receiving systemic anticancer treatment.
For medical oncologists, hematologists, oncology fellows, pharmacists, advanced practice providers, oncology nurses, residents, and medical students seeking a concise drug-focused oncology reference, this manual offers a structured and clinically relevant resource.
Its emphasis on practical prescribing information and toxicity management makes it particularly useful as a point-of-care reference or as a supplement to more comprehensive oncology textbooks. These observations are based on the uploaded source and are not intended as a comparative ranking against other references.
Disclaimer
MedBook 4 Free does not own copyrights to this video/book/software. We’re sharing this with our audience ONLY for educational purposes, and we highly encourage our visitors to purchase original licensed software/books.
If someone with copyrights wants us to remove this software/book, please contact us immediately. You can send an email to [email protected] for all DMCA / removal requests.